This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Motwani, J. G. Articles by Struthers, A. D. Search for Related Content PubMed PubMed Citation Articles by Motwani, J. G. Articles by Struthers, A. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAPTOPRIL FUROSEMIDE Medline Plus Health Information Heart Failure

Circulation, Vol 86, 439-445, Copyright © 1992 by American Heart Association

ARTICLES

Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure

JG Motwani, MK Fenwick, JJ Morton and AD Struthers
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK.

BACKGROUND. Ten chronic heart failure patients were studied on three occasions in randomized double-blind fashion to compare the acute hemodynamic, neurohormonal, and renal sodium-handling responses to 1 mg captopril versus 25 mg captopril, both in the absence of loop diuretic therapy and during furosemide-stimulated natriuresis. METHODS AND RESULTS. Compared with placebo, 1 mg captopril caused nonsignificant decreases in mean arterial pressure and circulating angiotensin II level and had no effect on glomerular filtration rate as determined by 51Cr-EDTA elimination. Captopril (25 mg) produced marked suppression of serum angiotensin II with or without oral furosemide (both p less than 0.002), a marked decrease in mean arterial pressure (p less than 0.001) that was accentuated by furosemide (p less than 0.00001), and a decrease in glomerular filtration rate (p = 0.0007). No difference from placebo in renal sodium excretion was noted with either 1 or 25 mg captopril in the absence of furosemide. In contrast, while 25 mg captopril caused slight attenuation of the natriuretic response to furosemide, 1 mg captopril significantly enhanced furosemide-induced natriuresis (p less than 0.05). No correlation was found in our patients between the natriuretic effect of furosemide and either absolute mean arterial pressure or change in mean arterial pressure during the furosemide phase of each study session. This suggests that blood pressure is not the important factor mediating the divergent renal responses to furosemide of the two captopril dosage regimens. CONCLUSIONS. We propose that in the face of furosemide-induced postglomerular vasodilatation in chronic heart failure, captopril at a starting dose of 1 mg (but not 25 mg) preserves enough circulating angiotensin II to maintain efferent arteriolar tone and thus glomerular filtration, while offsetting the antinatriuretic renal tubular effects of angiotensin II.

This article has been cited by other articles:

				J. G Motwani Review: Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 72 - 78. [Abstract] [PDF]

				M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]

				G. Castaneda-Hernandez, J. Verges, V. Pichette, L. Heroux, G. Caille, and P. du Souich Input Rate as a Major Determinant of Furosemide Pharmacodynamics: Influence of Fluid Replacement and Hypoalbuminemia Drug Metab. Dispos., March 1, 2000; 28(3): 323 - 328. [Abstract] [Full Text] [PDF]